Mylan Bids To Win EU Approval For Upjohn Merger

New Zealand Watchdog Also Raises Potential Concerns

Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.

Sale
Mylan may have to divest products to get its merger with Pfizer's Upjohn over the line • Source: Shutterstock

Shortly after announcing a delay in the merger to the second half of this year, Mylan has offered concessions to the European Commission’s department for competition to address antitrust concerns about its plans to join with Pfizer’s Upjohn mature brands and off-patent division.

A provisional deadline of 22 April has been set by the Commission for its decision, after Mylan put forward its concessions on 27 March

More from Deals

More from Business